Evidence map›Paper›PMID 33807165›Full record

ReviewBiomolecules2021

Screening Methods for Diagnosing Cystic Fibrosis-Related Diabetes: A Network Meta-Analysis of Diagnostic Accuracy Studies.

Vera Dóra Izsák, Alexandra Soós, Zsolt Szakács, Péter Hegyi, Márk Félix Juhász, Orsolya Varannai, Ágnes Rita Martonosi, Mária Földi, Alexandra Kozma, Zsolt Vajda and 2 more

Open access · goldAbstract readReviewNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Vera Dóra IzsákInstitute for Translational Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary.ORCID 0000-0002-4119-2382
Alexandra SoósInstitute for Translational Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary.
Zsolt SzakácsInstitute for Translational Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary.ORCID 0000-0002-7035-941X
Péter HegyiInstitute for Translational Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary.
Márk Félix JuhászInstitute for Translational Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary.
Orsolya VarannaiInstitute for Translational Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary.
Ágnes Rita MartonosiInstitute for Translational Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary.
Mária FöldiInstitute for Translational Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary.
Alexandra KozmaInstitute for Translational Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary.
Zsolt VajdaHeim Pál National Pediatrics Institute, 1089 Budapest, Hungary.
James Am ShawTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE1 7RU, UK.
Andrea PárniczkyInstitute for Translational Medicine, Medical School, University of Pécs, 7624 Pécs, Hungary.
University of Szeged · HUUniversity of Pecs · HUHeim Pál Országos Gyermekgyógyászati Intézet · HUNewcastle University · GB

Funding

European Union (European Regional Development Fund) within the framework of Programme Széchenyi 2020 and Human Resources Development Operational Programme Grant, GINOP-2.3.2-15-2016-00048 - STAY ALIVEEuropean Union (European Regional Development Fund) within the framework of Programme Széchenyi 2020. János Bolyai Research Scholarship of the Hungarian Academy of Sciences and Cystic Fibrosis Trust Strategic Research Center Grant (NU-000600; SRC-019) to EFOP-3.6.2-16-2017-00006 - LIVE LONGER
6 · The paper itself

Abstract

backgroundCystic fibrosis-related diabetes (CFRD) has become more common due to higher life expectancy with cystic fibrosis. Early recognition and prompt treatment of CFRD leads to improved outcomes.

methodsWe performed a network meta-analysis (NMA) in order to identify the most valuable diagnostic metrics for diagnosing CFRD out of available screening tools (index test), using the oral glucose tolerance test as a reference standard. Pooled sensitivity (Se), specificity (Sp), and superiority indices were calculated and used to rank the index tests.

resultsA total of 31 articles with 25 index tests were eligible for inclusion. Two-day, continuous glucose monitoring (CGM) ranked the highest (Se: 86% Sp: 76%), followed by glucose measurement from blood capillary samples (Se: 70%, Sp: 82%) and three-day CGM (Se: 96%, Sp: 56%). When we compared the CGM of different durations, two-day CGM performed best (Se: 88%, Sp: 80%), followed by three-day (Se: 96%, Sp: 59%) and six-day CGM (Se: 66%, Sp: 79%).

conclusionsConsidering its overall performance ranking, as well as the high sensitivity, two-day CGM appears to be a promising screening test for CFRD.

Indexed as

Blood GlucoseCystic FibrosisDiabetes MellitusGlucose Tolerance TestGlycated HemoglobinHumansMonitoring, PhysiologicBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humancontinuous glucose monitorcystic fibrosiscystic fibrosis-related diabetesoral glucose tolerance test

Identifiers

PMID33807165
PMCPMC8065857
OpenAlexW3148441289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.